SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-099107
Filing Date
2024-04-17
Accepted
2024-04-17 16:15:28
Documents
5
Period of Report
2024-05-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A d656970ddef14a.htm DEF 14A 393269
2 GRAPHIC g656970dsp043.jpg GRAPHIC 249325
3 GRAPHIC g656970dsp044.jpg GRAPHIC 100373
4 GRAPHIC g656970g06s06.jpg GRAPHIC 24008
5 GRAPHIC g656970g11l28.jpg GRAPHIC 48746
  Complete submission text file 0001193125-24-099107.txt   965413
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40656 | Film No.: 24851255
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)